Maze Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(68,935) | $(66,465) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 835 | 1,333 |
| Stock-based compensation expense | 16,296 | 6,463 |
| Non-cash lease expense | 1,674 | 1,543 |
| Amortization of premiums on marketable securities, net | 5 | — |
| Amortization of debt discount and debt issuance costs | 498 | — |
| Other items, net | 18 | 21 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,536) | (1,750) |
| Other assets | (412) | 18 |
| Accounts payable | 418 | 1,846 |
| Accrued expenses and other liabilities | (90) | (957) |
| Operating lease liabilities | (1,843) | (1,620) |
| Long-term liabilities | (1,094) | — |
| Net cash used in operating activities | (54,166) | (59,568) |
| Investing activities | ||
| Purchases of marketable securities | (186,031) | — |
| Maturities of marketable securities | 64,000 | — |
| Purchases of property and equipment | (200) | (692) |
| Net cash used in investing activities | (122,231) | (692) |
| Financing activities | ||
| Proceeds from underwritten registered offering, net | 145,659 | — |
| Payment of underwritten registered offering costs | (1,090) | — |
| Proceeds from debt issuance, net | 39,401 | — |
| Payment of debt issuance costs | (939) | — |
| Proceeds from exercise of stock option awards | 5,775 | 126 |
| Proceeds from issuance of common stock under the 2025 Employee Stock Purchase Plan | 998 | 612 |
| Payment of offering costs for private placement | (11) | — |
| Proceeds from initial public offering, net | — | 130,200 |
| Payment of initial public offering costs | — | (2,448) |
| Payment of success fee derivative | — | (500) |
| Net cash provided by financing activities | 189,793 | 127,990 |
| Net increase in cash, cash equivalents and restricted cash | 13,396 | 67,730 |
| Cash, cash equivalents and restricted cash at beginning of the period | 190,335 | 197,900 |
| Cash, cash equivalents and restricted cash at end of the period | $203,731 | $265,630 |
| Reconciliation to cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $202,643 | $264,541 |
| Restricted cash | 1,088 | 1,089 |
| Total cash, cash equivalents and restricted cash | $203,731 | $265,630 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.